IE
SABS icon

Israel Englander’s SAB Biotherapeutics SABS Stock Holding History

Israel Englander’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Sell
2,749,087
-283,610
-9% -$1.06M ﹤0.01% 2215
2026
Q1 		$11.6M Buy
3,032,697
+2,708,607
+836% +$10.8M ﹤0.01% 2036
2025
Q4 		$1.21M Buy
+324,090
New +$1.07M ﹤0.01% 4356
2025
Q2 		– Sell
-16,351
Closed -$22.1K – 6274
2025
Q1 		$22.1K Sell
16,351
-13,060
-44% -$29.9K ﹤0.01% 5622
2024
Q4 		$112K Sell
29,411
-22,535
-43% -$74K ﹤0.01% 5461
2024
Q3 		$140K Sell
51,946
-838
-2% -$2.32K ﹤0.01% 5526
2024
Q2 		$164K Sell
52,784
-1,266
-2% -$4.64K ﹤0.01% 5211
2024
Q1 		$245K Buy
+54,050
New +$298K ﹤0.01% 5258
2022
Q4 		– Sell
-3,855
Closed -$27K – 6985
2022
Q3 		$27K Sell
3,855
-2,567
-40% -$25.5K ﹤0.01% 6377
2022
Q2 		$93K Buy
+6,422
New +$135K ﹤0.01% 5967
2021
Q4 		– Sell
-19,131
Closed -$1.93M – 7311
2021
Q3 		$1.93M Buy
19,131
+15,465
+422% +$1.54M ﹤0.01% 3970
2021
Q2 		$365K Buy
+3,666
New +$364K ﹤0.01% 5562

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Israel Englander's SABS Position: Q2 2026 in Review

Israel Englander reduced its SAB Biotherapeutics (SABS) stake by 9.4% in Q2 2026, selling an estimated $1.06M and leaving 2,749,087 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2215.

Israel Englander first reported a position in SABS in Q2 2021 and has held it in 12 quarters since. The position peaked at $11.6M in Q1 2026. 86 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Israel Englander held 2,749,087 shares of SAB Biotherapeutics worth $10.7M as of Q2 2026.
  • Israel Englander sold 283,610 SAB Biotherapeutics shares in Q2 2026, an estimated $1.06M.
  • SAB Biotherapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2215 holding.
  • Israel Englander first reported a position in SAB Biotherapeutics in Q2 2021 and has held it in 12 quarters since.
  • Israel Englander's SAB Biotherapeutics position peaked at $11.6M in Q1 2026.
  • 86 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.